Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review
Cardiovascular Toxicology · 2024-11 · 24 (11) · 1174-1191
DOI: 10.1007/s12012-024-09918-6 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cardiovascular Toxicology, online erschienen am 10.09.2024. Verfasst von Sihan Tan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory …. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Infliximab, Lung Neoplasms, Myocarditis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Project of Sichuan, China, 1-3-5 project for disciplines of excellence.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 and its ligand (PD-1/PD-L1) as well as anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4), have been widely used for treating solid tumors. Myocarditis is a potentially lethal immune-related adverse events (irAEs) caused by ICIs therapy. The treatment of steroid-refractory myocarditis is challenging. We reported two non-small-cell lung cancer patients with steroid-refractory myocarditis induced by ICI. The symptoms were not resolved after pulse corticosteroid therapy and subsequent treatment including intravenous immunoglobulin and mycophenolate mofetil. Considering the level of serum interleukin (IL)-6 decreased by > 50% and level of serum tumor necrosis factor-α (TNF-α) increased during the course of the disease, infliximab was used. Myocarditis gradually alleviated after infliximab treatment. The cases revealed that specific cytokine inhibitors have promising roles in the treatment of steroid-refractory myocarditis. Infliximab could be considered for patients with low level of IL-6 and elevated level of TNF-α.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu,…
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu, 610041, Sichuan, China.
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu, 610041, Sichuan, China. liyalun@wchscu.cn.
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu, 610041, Sichuan, China. mrascend@163.com.
Förderung
- National Natural Science Foundation of China
- Science and Technology Project of Sichuan, China
- 1-3-5 project for disciplines of excellence
Zitieren
APA
Tan, S., Qi, C., Zeng, H., Wei, Q., Huang, Q., Pu, X., Li, W., Li, Y., & Tian, P. (2024). Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review. Cardiovascular Toxicology, 24(11), 1174-1191. https://doi.org/10.1007/s12012-024-09918-6
Vancouver
Tan S, Qi C, Zeng H, Wei Q, Huang Q, Pu X, et al. Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review. Cardiovascular Toxicology. 2024;24(11):1174-1191. doi:10.1007/s12012-024-09918-6
BibTeX
@article{Tan2024,
author = {Tan, Sihan and Qi, Chang and Zeng, Hao and Wei, Qi and Huang, Qin and Pu, Xin and Li, Weimin and Li, Yalun and Tian, Panwen},
title = {Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review},
journal = {Cardiovascular Toxicology},
year = {2024},
volume = {24},
number = {11},
pages = {1174--1191},
doi = {10.1007/s12012-024-09918-6}
}
EUVIMED